DK2443149T3 - Bace1-hæmmende antistoffer - Google Patents
Bace1-hæmmende antistoffer Download PDFInfo
- Publication number
- DK2443149T3 DK2443149T3 DK10726057.2T DK10726057T DK2443149T3 DK 2443149 T3 DK2443149 T3 DK 2443149T3 DK 10726057 T DK10726057 T DK 10726057T DK 2443149 T3 DK2443149 T3 DK 2443149T3
- Authority
- DK
- Denmark
- Prior art keywords
- gly
- bace1
- val
- leu
- ser
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (9)
1. Isoleret monoklonalt anti-BACEl-antistof, som består af 2 tunge og 2 lette læder, kendetegnet ved, at det monoklonale antistof hæmmer BACEl-medieret spaltning af beta-amyloid-precursor-protein (APP), og hvor det monoklonale antistof binder sig til en konformationel BACEl-epitop, der omfatter aminosyreresterne 332 til 334 fra sløjfe D og aminosyreresterne 376 til 379 fra sløjfe F fra BACE1 ifølge SEQ ID NO: 1.
2. Antistof ifølge krav 1, som endvidere er kendetegnet ved, at det secerneres af en hybridomcellelinje med accessionsnummer LMBP 6871CB.
3. Antistof ifølge krav 1 eller 2, som endvidere er kendetegnet ved, at det er et humaniseret monoklonalt antistof.
4. Aktivt fragment af antistoffet ifølge et hvilket som helst af kravene 1-3, kendetegnet ved, at fragmentet hæmmer BACEl-medieret spaltning af beta-amyloid-precursor-protein (APP) .
5. Hybridomcellelinje med accessionsnummer LMBP 6871CB.
6. Antistof ifølge et hvilket som helst af kravene 1-3 eller aktivt fragment ifølge krav 4 til anvendelse som lægemiddel.
7. Antistof ifølge et hvilket som helst af kravene 1-3 eller aktivt fragment ifølge krav 4 til anvendelse til forebyggelse og/eller behandling af Alzheimers sygdom.
8. Farmaceutisk sammensætning, som omfatter antistoffet ifølge et hvilket som helst af kravene 1-3 eller det aktive fragment ifølge krav 4 og mindst én/ét farmaceutisk acceptabel(t) bærer, adjuvans eller fortyndingsmiddel.
9. Antistof ifølge et hvilket som helst af kravene 1-3 eller aktivt fragment ifølge krav 4 til anvendelse i et diagnostisk assay.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09162713 | 2009-06-15 | ||
| PCT/EP2010/058403 WO2010146058A1 (en) | 2009-06-15 | 2010-06-15 | Bace1 inhibitory antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2443149T3 true DK2443149T3 (da) | 2016-12-12 |
Family
ID=40848528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10726057.2T DK2443149T3 (da) | 2009-06-15 | 2010-06-15 | Bace1-hæmmende antistoffer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8956614B2 (da) |
| EP (2) | EP2443149B1 (da) |
| JP (3) | JP5944822B2 (da) |
| AU (1) | AU2010261853B8 (da) |
| CA (1) | CA2764545C (da) |
| DK (1) | DK2443149T3 (da) |
| ES (1) | ES2602611T3 (da) |
| WO (1) | WO2010146058A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2443149T3 (da) | 2009-06-15 | 2016-12-12 | Vib Vzw | Bace1-hæmmende antistoffer |
| ES2607086T3 (es) * | 2010-11-10 | 2017-03-29 | F. Hoffmann-La Roche Ag | Métodos y composiciones para la inmunoterapia de enfermedades neuronales |
| CA2818173C (en) | 2010-11-30 | 2022-05-03 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| JP6134725B2 (ja) * | 2011-10-14 | 2017-05-24 | ジェネンテック， インコーポレイテッド | Ｂａｃｅ１のペプチド阻害剤 |
| US10729777B2 (en) | 2012-04-09 | 2020-08-04 | Case Western Reserve University | Compositions and methods for inhibiting the activity of LAR family phosphatases |
| EP2864346B1 (en) * | 2012-06-21 | 2018-10-17 | Synthon Biopharmaceuticals B.V. | Method of purifying an antibody |
| US10258672B2 (en) | 2014-10-09 | 2019-04-16 | Case Western Reserve University | Compositions and methods of treating root avulsion injury |
| EP3221364B1 (en) * | 2014-11-19 | 2020-12-16 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
| JP6993228B2 (ja) | 2014-11-19 | 2022-03-03 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法 |
| EP3634979A4 (en) * | 2017-06-05 | 2021-04-14 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| WO2019094608A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| WO2024008755A1 (en) | 2022-07-04 | 2024-01-11 | Vib Vzw | Blood-cerebrospinal fluid barrier crossing antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO2002047466A2 (en) * | 2000-10-27 | 2002-06-20 | The Johns Hopkins University School Of Medicine | Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof |
| US6794351B2 (en) | 2001-04-06 | 2004-09-21 | Kimberly-Clark Worldwide, Inc. | Multi-purpose cleaning articles |
| WO2009121948A2 (en) * | 2008-04-03 | 2009-10-08 | Vib Vzw | Single domain antibodies capable of modulating bace activity |
| HUE059078T2 (hu) * | 2009-02-20 | 2022-10-28 | Enhanx Biopharm Inc | Glutation-alapú hatóanyagszállító rendszer |
| DK2443149T3 (da) | 2009-06-15 | 2016-12-12 | Vib Vzw | Bace1-hæmmende antistoffer |
-
2010
- 2010-06-15 DK DK10726057.2T patent/DK2443149T3/da active
- 2010-06-15 AU AU2010261853A patent/AU2010261853B8/en not_active Ceased
- 2010-06-15 CA CA2764545A patent/CA2764545C/en not_active Expired - Fee Related
- 2010-06-15 EP EP10726057.2A patent/EP2443149B1/en not_active Not-in-force
- 2010-06-15 US US13/377,508 patent/US8956614B2/en not_active Expired - Fee Related
- 2010-06-15 EP EP16179153.8A patent/EP3118222A1/en not_active Withdrawn
- 2010-06-15 JP JP2012515465A patent/JP5944822B2/ja not_active Expired - Fee Related
- 2010-06-15 ES ES10726057.2T patent/ES2602611T3/es active Active
- 2010-06-15 WO PCT/EP2010/058403 patent/WO2010146058A1/en active Application Filing
-
2016
- 2016-02-12 JP JP2016024686A patent/JP2016147859A/ja active Pending
-
2017
- 2017-10-26 JP JP2017206883A patent/JP2018058844A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2602611T3 (es) | 2017-02-21 |
| EP2443149B1 (en) | 2016-08-10 |
| JP2012530105A (ja) | 2012-11-29 |
| WO2010146058A1 (en) | 2010-12-23 |
| JP2018058844A (ja) | 2018-04-12 |
| US20120237526A1 (en) | 2012-09-20 |
| CA2764545A1 (en) | 2010-12-23 |
| AU2010261853A1 (en) | 2012-01-19 |
| CA2764545C (en) | 2019-05-14 |
| EP2443149A1 (en) | 2012-04-25 |
| AU2010261853B8 (en) | 2015-02-26 |
| JP5944822B2 (ja) | 2016-07-05 |
| JP2016147859A (ja) | 2016-08-18 |
| AU2010261853B2 (en) | 2015-01-22 |
| US8956614B2 (en) | 2015-02-17 |
| EP3118222A1 (en) | 2017-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2443149T3 (da) | Bace1-hæmmende antistoffer | |
| DK2281005T3 (da) | Enkeltdomæneantistoffer, der er i stand til at modulere bace1-aktivitet | |
| RU2760875C1 (ru) | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения | |
| EP2084190B1 (en) | Lingo binding molecules and pharmaceutical use thereof | |
| CA3180222A1 (en) | Tau binding compounds | |
| CN117398459A (zh) | 抗EphA4抗体 | |
| EP1725870A1 (en) | Anti-lipid rafts antibodies | |
| US10377834B2 (en) | Single domain antibodies capable of modulating BACE activity | |
| EP2484695A1 (en) | A method for the production of hybridoma cell lines producing monoclonal antibodies capable to specifically binding to a human C44-fragment of agrin | |
| US9796778B1 (en) | Antibodies against pathological forms of TDP-43 and uses thereof | |
| US20240150449A1 (en) | Antibodies against tdp-43 and methods of using the same | |
| Köppen et al. | Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis | |
| WO2023250388A1 (en) | Tau binding compounds | |
| IL294932A (en) | Antibodies against ide and their uses |